Astrazeneca

FromAstraZeneca ([email protected])
Subject (52)Eplontersen Phase III trial met co-primary endpoints
Preheader (150)Eplontersen met co-primary and secondary endpoints in interim analysis of the NEURO-TTRansform Phase III trial for hereditary transthyretin-mediated a
Typography
Arial
Colors
Text Analysis
Body Words215
Subject Words7
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px778 px
X-Spam Score0.4
Preheader OptimizedNo
Timing
Day of WeekMonday
TimeEvening

Eplontersen Phase III trial met co-primary endpoints

Eplontersen met co-primary and secondary endpoints in interim analysis of the NEURO-TTRansform Phase III trial for hereditary transthyretin-mediated a
Eplontersen Phase III trial met co-primary endpoints